Hamilton, Bermuda, April 10, 2024 (GLOBE NEWSWIRE) -- Management to host conference call today, April 10, at 8.30 a.m. EDTRNA delivery business progressing with new collaborations, potential new...
HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Altamiras polyKRASmut siRNA shown to knock down at least 65-91% of KRAS mutations in colorectal, non-small cell lung, and pancreatic...
HAMILTON, BERMUDA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Company hosts Investor and Business Update call on December 11 at 8:30 a.m. ETPartial spin-off of Bentrio® business first step in transition to...
Altamira Therapeutics' corporate redesign has been more than a year in the making as the biotech looks to offload legacy assets while fully pivoting toward RNA delivery. The moves have come at the cost of a quarter of its existing workforce, with the headcount changes just now coming into view.
- Partial spin-off of Bentrio® completed to increase focus on RNA delivery activities - Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29,...
Initiates Strategic Repositioning to Focus on Company™s Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue ...
Altamira Announces Patent Office Decision to Grant for Intranasal Betahistine